Bukwang Pharmaceutical unveils new corporate identity after 66 years, pledging innovation

Bukwang Pharmaceutical unveiled a new corporate identity and slogan Friday, marking its 66th anniversary with a visual overhaul designed to signal its ambitions as a global pharmaceutical company.

The redesign applied a modern visual language to the company's long-established reputation, with the goal of communicating its identity and future vision more clearly.

The new symbol retains the flame motif that has long represented the company's core values of trust, solidity and passion, while recasting the form in a contemporary style.

A straight vertical pillar at the center of the symbol represents the structural foundation of life science research and core technology, while curved forms on either side extend outward to convey the energy of technology and innovation.

The logotype uses a refined typeface to improve legibility and harmonizes the symbol's protrusions with the logotype's serifs. The brand color has been changed from bright green to "Bukwang Deep Green," a deeper shade intended to convey stability and accountability. The English logotype also reflects the pillar and wing forms of the symbol, creating consistency between the Korean and English versions.

The company adopted "Built on Trust, Key to Innovation" as its new slogan. "Built on Trust" refers to more than six decades of accumulated credibility, while "Key to Innovation" expresses the vision of opening new frontiers through continuous research. The slogan also incorporates the initials B and K to embed the company's distinct identity.

The rebrand is seen as a symbolic declaration of the company's intent to shed the conservative image associated with legacy pharmaceutical companies and to signal — both internally and externally — its commitment to drug development and an R&D-driven transformation.

"This CI renewal establishes a new identity rooted in our 66-year history and sets out a direction for the future," a Bukwang Pharmaceutical official said. "We will build on the trust we have accumulated to open new possibilities in the pharmaceutical industry."